3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
2
Myeloid
1
Head & Neck
1
Classical hematology
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
79
fludarabine phosphate
75
Busulfan
53
Whole-Body Irradiation
51
Mycophenolic Acid
50
Cyclosporine
47
Peripheral Blood Stem Cell Transplantation
46
fludarabine
42
Antilymphocyte Serum
37
Melphalan
36
Tacrolimus
35
Filgrastim
30
Cord Blood Stem Cell Transplantation
27
Radiotherapy
23
Methotrexate
22
Cytarabine
22
Methylprednisolone
19
Granulocyte Colony-Stimulating Factor
18
apixaban
17
Thiotepa
17
Dalteparin
13
thymoglobulin
12
Rivaroxaban
12
Alemtuzumab
12
eltrombopag
11
ferric carboxymaltose
10
Surveys and Questionnaires
10
Etoposide
10
Epoetin Alfa
10
Cyclosporins
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
magrolimab
×
Classical hematology
×
Clear all
NCT05829434
2024-02-12
MAGROLIC
University of Leipzig
Phase 2
Withdrawn